| US 7,517,670 B2 | ||
| Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity | ||
| Pablo Umaña, Zürich (Switzerland); Joël Jean-Mairet, Zürich (Switzerland); and James E Bailey, Zürich (Switzerland); M. Sean Bailey, legal representative | ||
| Assigned to GlycArt Biotechnology AG, Schlieren-Zürich (US) | ||
| Filed on Aug. 05, 2003, as Appl. No. 10/633,697. | ||
| Application 10/633697 is a division of application No. 09/294584, filed on Apr. 20, 1999, granted, now 6,602,684. | ||
| Claims priority of provisional application 60/082581, filed on Apr. 20, 1998. | ||
| Prior Publication US 2005/0079605 A1, Apr. 14, 2005 | ||
| This patent is subject to a terminal disclaimer. | ||
| Int. Cl. C12N 15/12 (2006.01); C12N 15/63 (2006.01); A61K 39/00 (2006.01) | ||
| U.S. Cl. 435—69.1 [435/320.1; 435/455; 435/456] | 67 Claims |
| 1. A method for producing a recombinant antibody having increased Fc mediated cellular cytotoxicity or increased Fc receptor
binding affinity, comprising:
(a) providing a mammalian host cell that expresses a recombinant antibody comprising an IgG Fc region containing N-linked
oligosaccharides;
(b) glycoengineering said host cell, wherein said glycoengineering comprises genetically manipulating said host cell so that
said host cell has a decreased level of activity of at least one glycoprotein-modifying glycosyltransferase;
(c) culturing said glycoengineered host cell under conditions which permit the production of said recombinant antibody; and
(d) isolating said recombinant antibody;
wherein said recombinant antibody has increased Fc-mediated cellular cytotoxicity or increased Fc receptor binding affinity
compared to the corresponding antibody produced by the same host cell that has not been glycoengineered.
|